Physician profile
Xu Wang
NPI 1558577460
$345.76
in general payments reported to CMS, 2019-2025
9 companies · $41.35 in 2025
The $41.35 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.36 · 2023: $100 · 2024: $115 · 2025: $41.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $115.05 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Astrazeneca Pharmaceuticals LP | $100.00 | 2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.36 | 2019 | |
| Abbott Laboratories | $20.93 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Heartflow, INC. | $20.42 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xu Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.